New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

UK study finds evidence of waning antibody immunity to Covid-19 over time

Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community.

2

Covid-19 heart changes raise death risk; virus may be lead killer of young adults during surges

In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, a new study may help identify which Covid-19 patients with signs of heart injury are at higher risk for death.

3

Weekly U.S. Covid-19 deaths up 15%, new cases rise 24%

The number of new Covid-19 cases in the United States last week rose 24% to more than 485,000 while the number of tests performed rose 5.5%, according to a Reuters analysis of state and county reports.

4

FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease

FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace   FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined conference. The analyses looked at associations between the […]

5

AstraZeneca’s Covid-19 Vaccine Boosts Immune Response in Older, Younger Adults

Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.

7

Spectrum Pharmaceuticals Sees Delay from FDA on Eflapegrastim BLA

Spectrum Pharmaceuticals announced that an inspection of the Hanmi Bioplant in South Korea will be necessary before the U.S. Food and Drug Administration can approve the company’s Biologics License Application for Rolontis (eflapegrastim).